Mirabegron
Overactive Bladder
VA Office of Research and DevelopmentSmall moleculePhase 4 / ApprovedActive
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 89/ 100
Competitive context
13 Active assets in the Overactive Bladder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TROSPIUM Allergan | Phase 4 | BB |
Nabiximols Jazz Pharmaceuticals | Phase 3 | BB |
SOLIFENACIN VA Office of Research and Development | Phase 4 | B |
Oxybutynin University of California, Davis | Phase 3 | B |
Fesoterodine Sir Mortimer B. Davis - Jewish General Hospital | Phase 4 | B |
View all 22 →
Same molecule, other indications
Mirabegron is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →